MUC20-OT1

Across TCGA pan-cancer cohorts, MUC20-OT1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MUC20-OT1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MUC20-OT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MUC20-OT1 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

LIHC, KIRC, and THCA are the cancer types where MUC20-OT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MUC20-OT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.592	<.001	8	view →
KIRC	All	All	+0.446	<.001	8	view →
THCA	Female	II,III,IV	−0.675	<.001	7	view →
BRCA	Female	All	−0.324	.001	6	view →
CHOL	Female	All	+1.599	<.001	5	view →
KICH	All	II,III,IV	+0.925	.002	4	view →
LUSC	All	All	+0.651	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MUC20-OT1–LIHC

Open the LIHC breakdown →